Roivant Sciences is a company built on a simple idea: big pharmaceutical firms leave promising drugs on the shelf, and a leaner parent can pick them up and push them forward faster. Full nameRoivant Sciences Ltd. Tickers / exchangeROIV (Nasdaq); ROIV.BSX (Bermuda Stock Exchange) HeadquartersLondon, United Kingdom (operating); incorporated in Bermuda SectorPharmaceuticals / biotechnology Employees908 (2024) Market valueNot published in available sources Yearly sales (revenue)$8.26 million (fiscal year ended March 31, 2026) Net profitNet loss of approximately $1.0 billion (fiscal 2026) Net marginNegative (loss-making) Return on equityNegative (loss-making) Price-to-earningsNot meaningful …
Company Intelligence — Institutional Access
This dossier is part of our Company Intelligence database.
Full profiles, exchange dossiers and the regional intelligence briefs are available to institutional subscribers. Professional from US$490/year, Corporate US$1,450, Institutional US$3,900.
See institutional access →Already a subscriber? Log in.
Part of LatAm Company Intelligence
This company profile belongs to The Rio Times' research on every listed company and exchange in Latin America and the Caribbean. Browse the full intelligence hub →
Not ready to buy? Try Company Intelligence free for 14 days →
Editorial responsibility: Matthias Camenzind, Editor-in-Chief · Editorial standards · Report an error
Read More from The Rio Times
The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →